A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
An Almost Normal Life Expectancy for People With HIV?
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
A 15-Year Jump in Life Expectancy for People With HIV
Misleading News Reports Suggest HIV Cure Is Near
New HIV Drug Class Shows Promise
Gene Therapy Shows Promise in Controlling HIV
Potential Microbicide Tricks HIV Into Sudden Death
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

November 18, 2010

FDA Panel Recommends Approval of Gardasil for Anal Cancer Prevention

A U.S. Food and Drug Administration (FDA) advisory panel has recommended that the agency approve Gardasil to prevent anal cancer in both men and women, according to reporting by Reuters. The vaccine is currently approved to prevent cervical cancer in women and genital warts in both women and men.

Gardasil is a vaccine that targets the strains, or types, of human papillomavirus (HPV) that cause genital warts (types 6 and 11) in both men and women and cervical cancer (types 16 and 18) in women. It was approved in 2006 to prevent both conditions in girls and women ages 9 to 26. The vaccine was initially approved only for girls and younger women. It targeted this age group because the vaccine doesn’t work once a person is already infected with HPV, and infection usually occurs soon after people become sexually active.

The FDA approved Gardasil in 2009 to prevent genital warts in boys and young men, which it does quite effectively, but it had not yet been approved to prevent anal cancer in either gender. Up to 80 percent of all anal cancers are caused by the same HPV strains that cause cervical cancer.

Though the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices strongly recommends Gardasil treatment for girls and young women—the committee’s recommendation highly influences whether providers offer a vaccine and and whether insurance companies cover it—the committee chose not to recommend Gardasil for boys and young men, citing a lack of sufficient data on the vaccine’s effect at preventing precancerous anal lesions.

Since then, Merck submitted those data to the FDA, and the FDA’s Vaccines and Related Biological Products Advisory Committee felt that the data were strong enough to warrant approval for the prevention of anal cancer in both men and women.

“I do think the data are sufficiently strong,” said the panel’s chairman, Jose Romero, MD, a pediatric infectious disease expert at Arkansas Children’s Hospital

The FDA is not obligated to follow its advisory panels’ recommendations, but it usually does. If that’s the case, then activists hope that the CDC’s ACIP will reconsider its previous position on immunization of boys and men.

Merck is also hoping to get approval for Gardasil this year for older women between the ages of 27 and 45.

Search: FDA, Gardasil, human papillomavirus, HPV, anal cancer, genital warts, cervical dysplasia


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (1 total)


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    andais
    Red House
    West Virginia


    usuallyhappy
    Palm Springs
    California


    sefarady
    Palm Springs
    California


    HOTROD2010
    houston
    Texas
Click here to join POZ Personals!
Conference Coverage

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


20th Conference on Retroviruses and Opportunistic Infections
(CROI 2013)
Atlanta, GA
March 3 - 7, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.